ABNCoV2

ABNCoV2
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration		Intramuscular

ABNCoV2 is a COVID-19 vaccine candidate developed by Bavarian Nordic.[1][2][3][4]

References

  1. ↑ "Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial". Bavarian Nordic. 8 March 2021. Retrieved 13 April 2021.
  2. ↑ "Safety and Tolerability of ABNCoV2 (COUGH-1)". ClinicalTrials.gov. 9 April 2021. NCT04839146. Retrieved 13 April 2021.
  3. ↑ "Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine". Bavarian Nordic. 23 August 2021. Retrieved 24 August 2021.
  4. ↑ "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects". ClinicalTrials.gov. 14 October 2021. NCT05077267. Retrieved 14 October 2021.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.